Lenacapavir approved in the US for multidrug resistant HIV

Simon Collins, HIV i-Base

On 22 December, the US FDA approved the capsid inhibitor lenacapavir for multidrug resistant HIV. [1]

Lenacapavir is a long-acting drug given by subcutaneous injection.

It was approved in the EU by the EMA in August 2022, [2]


  1. Gilead press release Sunlenca (lenacapavir) receives FDA approval as a first-in-class, twice-yearly treatment option for people living with multi-drug resistant HIV. (22 December 2022).
  2. Lenacapavir approved in the EU and UK to treat multidrug resistant HIV. HTB September 2022.

This report was first posted online in December 2022.

Links to other websites are current at date of posting but not maintained.